Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Gbetiokun-3 Update

10 Jul 2019 07:00

RNS Number : 0099F
Eland Oil & Gas PLC
10 July 2019
 

10 July 2019

Eland Oil & Gas PLC

("Eland" or the "Company")

Gbetiokun-3 Update

 

Eland Oil & Gas PLC (AIM:ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, is pleased to announce that a remedial tubing patch has been installed on the Gbetiokun-3 well in licence OML40.

 

As previously announced ("OML40 Operational Update", 25 June 2019) we have been undertaking necessary remedial work on the Gbetiokun-3 short string. The well was drilled as an appraisal well in Q4 2018 with the dual completion on the D9000 and E4000 reservoirs being installed in Q1 2019. During pressure testing, a small leak was identified on the shallower D9000 completion string. Following further diagnostic logging, the leak was located, and a remedial tubing patch has now been successfully installed.

 

At present, the short string is being produced with the temporary facilities on location. Initial gross rates of some 3,880 bopd have been recorded at a choke size of 36/64". The deep E4000 interval was tested in Q1 2019 and achieved choke-limited gross rates of 3,000 bopd, in line with pre-drill expectations.

 

The company expects the field to be brought onstream in July through the Early Production Facility, presently being installed, with initial gross production of approximately 12,000 bopd (net: 5,400 bopd) from the Gbetiokun-1 and -3 wells.

 

George Maxwell, CEO of Eland, commented:

 

"We are pleased to have successfully completed the remedial work on Gbetiokun-3 and are very happy with the achieved flow-rates of almost 7,000 bopd. With Gbetiokun-1 performance already established at over 5,000 bopd, we look forward to updating all shareholders as we bring the field on stream later this month."

 

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Ronald Bain, CFO

Finlay Thomson, IR

 

Peel Hunt LLP, Nominated Adviser & Joint Broker (+44 (0)20 7418 8900)

Richard Crichton

David McKeown

 

Stifel Nicolaus Europe Limited, Joint Broker (+44 (0)20 7710 7600)

Callum Stewart

Nicholas Rhodes

Ashton Clanfield

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg

Tom Huddart

Monique Perks

 

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DRLFMGGNGLDGLZZ
Date   Source Headline
15th Nov 20062:50 pmRNSAnnual Report
25th Oct 20062:18 pmRNSBlocklisting Interim Review
25th Oct 20067:30 amBUSElan Reports Third Quarter 2006 Financial Results
24th Oct 20061:00 pmBUSTYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
18th Oct 20068:42 amRNSHolding in Company
10th Oct 20067:00 amBUSNotice of Results
6th Oct 20062:07 pmBUSNew Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
4th Oct 20061:00 pmBUSHealth Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review
29th Sep 20062:00 pmBUSNew Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
11th Sep 200611:57 amRNSFinancial Statements
9th Aug 20068:58 amRNSHolding in Company
2nd Aug 20065:26 pmRNSDirector/PDMR Shareholding
2nd Aug 200612:12 pmRNSHolding in Company
29th Jun 200612:32 pmRNSHolding in Company
21st Jun 200610:01 amRNSHolding in Company
15th Jun 20068:20 amRNSHolding in Company
7th Jun 20068:02 amRNSFurther re Appointment
1st Jun 200611:58 amRNSHolding in Company
25th May 20063:31 pmRNSHolding in Companies
25th May 200612:37 pmRNSHolding in Company
19th May 20065:51 pmRNSDirectors/PDMR Shareholding
19th May 200610:56 amRNSHolding in Company
17th May 200612:16 pmRNSHolding in Company
12th May 20061:45 pmRNSDirector/PDMR Shareholding
24th Apr 200611:36 amRNSHolding in Company
20th Apr 20064:44 pmRNSDocument Availability
19th Apr 20063:30 pmRNSHolding in Company
13th Apr 200612:51 pmRNSHolding in Company
13th Apr 200612:04 pmRNSAnnual Information Update
10th Apr 200612:42 pmRNSBrochure of Particulars
3rd Apr 20063:39 pmRNSBrochure of Particulars
13th Mar 200611:47 amRNSHoldings in Company
10th Mar 20063:24 pmRNSDirector/PDMR Shareholding
9th Mar 20067:30 amRNSRestoration of Listing
9th Mar 20067:01 amRNSOL Notice - Restoration
7th Mar 20061:00 pmRNSSuspension - Elan Corp Plc
7th Mar 20061:00 pmRNSOL Notice - Suspension
15th Feb 200610:15 amRNSBrochure of Particulars
10th Feb 20064:55 pmRNSDirector/PDMR Shareholding
9th Feb 20065:32 pmRNSDirector/PDMR Shareholding
9th Feb 20063:54 pmRNSHolding in Company
8th Feb 200610:56 amRNSDirector/PDMR Shareholding
3rd Feb 20069:58 amRNSDirector/PDMR Shareholding
25th Jan 200611:19 amRNSHolding in Company
9th Dec 20054:02 pmRNSDirector/PDMR Shareholding
17th Nov 20052:31 pmRNSRE:Director/PDMR Shareholding
1st Nov 20055:32 pmRNSDirector/PDMR Shareholding
22nd Sep 20059:43 amRNSRe: Brochure of Particulars
23rd Aug 20055:12 pmRNSDirector/PDMR Shareholding
21st Jun 200511:32 amRNSBrochure of Particulars

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.